1166827-44-6

• 常用中文名：AZD7687
• 常用英文名：AZD7687
• CAS号：1166827-44-6
• 分子式：C₂₁H₂₅N₃O₃
• 分子量：367.44200
• 相关类别： 信号通路 代谢酶/蛋白酶 酰基转移酶
• 发布时间：2017-06-21 10:05:50
• 更新时间：2024-01-11 10:33:31
• AZD7687是hDGAT1抑制剂,IC50为80 nM。

名称

• 中文名: AZD7687
• 英文名: 2-[4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl]acetic acid
• 英文别名: {trans-4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl}acetic acid; 2-((1r,4r)-4-(4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl)cyclohexyl)acetic acid; AZD7687

物化性质

• 分子式: C₂₁H₂₅N₃O₃
• 分子量: 367.44200
• 精确质量: 367.19000
• PSA: 107.16000
• LogP: 4.49200
• 储存条件: 2-8℃

生物活性

• 描述: AZD7687是hDGAT1抑制剂,IC50为80 nM。
• 相关类别:
  信号通路 >> 代谢酶/蛋白酶 >> 酰基转移酶
  研究领域 >> 代谢疾病
• 参考文献:

  [1]. Barlind JG, et al. Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). J Med Chem. 2012 Dec 13;55(23

  [2]. Denison H, et al. Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study. Diabetes Obes Metab. 2013 Feb;15(2):136-43.

  [3]. Denison H, et al. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes Obes Metab. 2013 Oct 4.

合成路线

1166827-45-7 ~99% 1166827-44-6

文献：ASTRAZENECA AB; ASTRAZENECA UK LIMITED Patent: WO2009/81195 A1, 2009 ; Location in patent: Page/Page column 51 ; WO 2009/081195 A1

1166831-68-0 ~80% 1166827-44-6

文献：ASTRAZENECA AB; ASTRAZENECA UK LIMITED Patent: WO2009/81195 A1, 2009 ; Location in patent: Page/Page column 168-169 ; WO 2009/081195 A1